Adverse Cardiovascular Effects of the Coxibs
Top Cited Papers
- 9 March 2005
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (7), 2251-2257
- https://doi.org/10.1021/jm0402059
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDsAtherosclerosis, 2004
- A coxib a day won't keep the doctor awayThe Lancet, 2004
- Coxibs—Beyond the GI TractJournal of Pain and Symptom Management, 2003
- The Second Generation of COX-2 InhibitorsDrugs, 2003
- COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expressionProceedings of the National Academy of Sciences, 2002
- Transcriptional Regulation of Cyclooxygenase-1 by Histone Deacetylase Inhibitors in Normal Human Astrocyte CellsPublished by Elsevier ,2002
- Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2Science, 2002
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000